Categories: News

Access Vascular Inc. Partners with Healthcare Insights to Develop New MedTech Value-Based Care Program

Access Vascular aims to usher in new model of value-based care delivery for medical devices as it supports hospitals in their mission to transform vascular access outcomes

BILLERICA, Mass., Feb. 10, 2022 (GLOBE NEWSWIRE) — Access Vascular, Inc. (AVI), today announced its partnership with Healthcare Insights (HCIS) to build a value-based care program that can more broadly support hospital customers as they deploy the company’s groundbreaking biomaterial-based catheters to improve vascular access medical and economic outcomes.

“While not yet uniformly implemented across the U.S. healthcare system, value-based care is coming to MedTech,” said James Biggins, CEO at Access Vascular, Inc. “We are excited and honored to partner with HCIS to craft our own innovative approach and to help lay the foundation for how other medical device companies can more effectively work with hospitals in this coming era of medicine.”

AVI is leveraging decades of hospital administration, clinical and reimbursement expertise from HCIS in the development of its outcome-based care program for hospitals in the United States. The program focuses on helping acute care facilities reduce practice variation and standardize procedural practice for improved outcomes and reduced costs associated wth vascular access complications such as thrombosis, infections, replacments and readmissions.

“Two recent studies of AVI’s HydroPICC® and HydroMID® devices demonstrated a significant reduction – in some cases as much as 100% – in complications such as occlusions, replacements, Deep Vein Thrombosis (DVT) and phlebitis as compared to traditional catheters,” said Dr. Gary Ansel, principal at HCIS. “This positions AVI to play a significant role in improving medical and economic outcomes for vascular access procedures, serving as the basis for a true value-based care solution.”

For more information about Access Vascular and its novel biomaterial-based catheters, please visit www.accessvascularinc.com.

About Access Vascular
Access Vascular was founded to address the most common and costly complications of intravenous therapy: infection, thrombosis, and phlebitis. Taking a foundationally different approach to thrombus reduction, the company manufactures intravenous catheters from a hydrophilic material which retains significant amounts of water. Engineered to mimic the body’s natural chemistry, Access Vascular catheters are designed to evade the foreign body response and complications that come with it. Our award-winning, FDA-cleared products are HydroPICC® and HydroMID®. For more information, please visit www.accessvascularinc.com.

About Healthcare Insights
Healthcare Insights brings unparalleled expertise from pioneers in medical device and healthcare delivery innovation to your team to help map your path to success — right from the beginning. For more information, please visit www.healthcareinsights.io.

Media Contact:
Anastasia Mironova
VP, Strategy & Marketing
(206) 778-6685

Staff

Recent Posts

Med Holdings Group, Inc. (FKA Yuka Group, Inc.) Announces Acquisition Of Medsmart Wellness Centers, Inc.

DENVER, CO / ACCESSWIRE / March 22, 2024 / (OTC Pink:YUKA) Med Holdings Group, Inc.…

44 mins ago

GE HealthCare Announces Cash Dividend for First Quarter of 2024

CHICAGO--(BUSINESS WIRE)--The Board of Directors of GE HealthCare Technologies Inc. (Nasdaq: GEHC) today declared a…

4 hours ago

GE HealthCare to Feature Latest Technologies in Interventional Radiology Focused on Precision Care at SIR 2024

Multi-modality showcase brings hands-on experience to care delivery for a wide range of vascular diseases…

4 hours ago

Smartsheet Names Katie Rooney to Board of Directors

Experienced global CFO adds depth in financial strategy and operating excellence to Smartsheet boardBELLEVUE, Wash.--(BUSINESS…

4 hours ago

The Centers for Medicare & Medicaid Services Revise National Coverage Determination for Stem Cell Transplantation

The Centers for Medicare & Medicaid Services revise the National Coverage Determination of allogeneic hematopoietic…

4 hours ago

Cocrystal Pharma Receives Pre-IND Responses from the FDA on Oral CC-42344 for Treating Influenza A

Feedback provides greater clarity on regulatory requirements for planned Phase 2b trial BOTHELL, Wash. (March…

5 hours ago